Celldex Therapeutics (NASDAQ:CLDX) Raised to Buy at ValuEngine

ValuEngine upgraded shares of Celldex Therapeutics (NASDAQ:CLDX) from a hold rating to a buy rating in a research note published on Tuesday morning, ValuEngine reports.

CLDX has been the topic of several other research reports. Zacks Investment Research raised shares of Celldex Therapeutics from a hold rating to a buy rating and set a $2.25 price objective on the stock in a research report on Wednesday, October 9th. HC Wainwright reiterated a buy rating and issued a $19.00 target price on shares of Celldex Therapeutics in a research note on Monday, November 11th.

Shares of Celldex Therapeutics stock traded up $0.01 during trading hours on Tuesday, hitting $2.57. 3,473 shares of the company’s stock traded hands, compared to its average volume of 282,499. Celldex Therapeutics has a 12-month low of $2.01 and a 12-month high of $11.63. The stock has a market capitalization of $41.29 million, a price-to-earnings ratio of -0.38 and a beta of 3.42. The company has a fifty day simple moving average of $2.38 and a 200-day simple moving average of $2.43. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.32 and a quick ratio of 6.32.

Celldex Therapeutics (NASDAQ:CLDX) last released its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.75) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.84) by $0.09. The company had revenue of $0.55 million for the quarter, compared to analysts’ expectations of $1.26 million. Celldex Therapeutics had a negative return on equity of 43.03% and a negative net margin of 1,119.84%. On average, analysts forecast that Celldex Therapeutics will post -3.85 EPS for the current fiscal year.

Institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC bought a new position in Celldex Therapeutics during the third quarter valued at $30,000. Cresset Asset Management LLC purchased a new stake in Celldex Therapeutics in the second quarter worth $1,227,000. Morgan Stanley raised its stake in shares of Celldex Therapeutics by 372.1% in the second quarter. Morgan Stanley now owns 11,132 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 8,774 shares during the period. A.R.T. Advisors LLC raised its stake in shares of Celldex Therapeutics by 70.1% in the second quarter. A.R.T. Advisors LLC now owns 52,741 shares of the biopharmaceutical company’s stock valued at $141,000 after buying an additional 21,741 shares during the period. Finally, BlackRock Inc. lifted its position in shares of Celldex Therapeutics by 12.5% during the 2nd quarter. BlackRock Inc. now owns 340,938 shares of the biopharmaceutical company’s stock valued at $914,000 after buying an additional 37,820 shares during the last quarter. Institutional investors and hedge funds own 24.50% of the company’s stock.

About Celldex Therapeutics

Celldex Therapeutics, Inc engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379.

Featured Story: S&P 500 Index

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.